Drugs / MK-8150
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01656408 | Aug 2012 → May 2013 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 1 | NCT01590810 | May 2012 → Jan 2013 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01590810 ↗ |
| Modality | Other / unclassified | “The novel nitric oxide donor MK-8150 induced significant blood-pressure lowering in dogs and humans for up to 14 days.” PMID 27561272 ↗ Aug 2016 |
| Route | Oral | “Participants will receive alternating single rising oral doses of MK-8150 or placebo” NCT01590810 ↗ |